Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000025.xml
Download PDF
Horm Metab Res
DOI: 10.1055/a-2641-1207
DOI: 10.1055/a-2641-1207
Mini-Review
The Role of Growth Hormone-Releasing Hormone and the Hypothalamic–Pituitary–Somatotropic Axis in Aging: Potential Therapeutic Applications and Risks
Supported by: Deutsche Forschungsgemeinschaft 288034826, 314061271
Abstract
Aging is marked by a gradual decline in multiple physiological functions, increasing the risk of age-related disorders. Multiple factors have been identified as contributors to aging, many of which are regulated by the hypothalamus. Growth hormone-releasing hormone (GHRH) produced in the hypothalamus is a key regulator of growth hormone (GH) secretion. With aging, both GHRH and GH levels decline, leading to muscle loss, increased fat accumulation, metabolic dysregulation, and cognitive impairments. GH replacement therapy has been explored as a potential intervention to counteract these effects; however, its long-term use is associated with significant risks, including metabolic disturbances, cardiovascular complications, and potential cancer promotion. In contrast, studies suggest that GHRH-based therapies can improve body composition, muscle strength, cognitive function, and cardiovascular health while avoiding the risks linked to direct GH administration. Additionally, preclinical findings indicate that GHRH agonists may offer cardioprotective and immunomodulatory benefits. In this review, we summarize current knowledge on the roles of GHRH and GH in aging, highlight the limitations of GH-based therapies, and discuss the potential of GHRH-based approaches in mitigating age-related decline and improving health span.
Publication History
Received: 25 February 2025
Accepted after revision: 14 June 2025
Article published online:
11 July 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Kim K, Choe HK. Role of hypothalamus in aging and its underlying cellular mechanisms. Mech Ageing Dev 2019; 177: 74-79
- 2 Granata R, Leone S, Zhang X. et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol 2025; 21: 180-195
- 3 Guillemin R, Brazeau P, Bohlen P. et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982; 218: 585-587
- 4 Montero-Hidalgo AJ, Del Rio-Moreno M, Perez-Gomez JM. et al. Update on regulation of GHRH and its actions on GH secretion in health and disease. Rev Endocr Metab Disord 2025; 26: 305-320
- 5 Khorram O, Garthwaite M, Golos T. The influence of aging and sex hormones on expression of growth hormone-releasing hormone in the human immune system. J Clin Endocrinol Metab 2001; 86: 3157-3161
- 6 Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39
- 7 Lesser GT, Deutsch S, Markofsky J. Use of independent measurement of body fat to evaluate overweight and underweight. Metabolism 1971; 20: 792-804
- 8 Anawalt BD, Merriam GR. Neuroendocrine aging in men. Andropause and somatopause. Endocrinol Metab Clin North Am 2001; 30: 647-669
- 9 Martin FC, Yeo AL, Sonksen PH. Growth hormone secretion in the elderly: ageing and the somatopause. Baillieres Clin Endocrinol Metab 1997; 11: 223-250
- 10 Hersch EC, Merriam GR. Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: fountain of youth or pool of tantalus?. Clin Interv Aging 2008; 3: 121-129
- 11 Ho KY, Evans WS, Blizzard RM. et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987; 64: 51-58
- 12 Jorgensen JO, Flyvbjerg A, Lauritzen T. et al. Dose-response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. J Clin Endocrinol Metab 1988; 67: 36-40
- 13 Pavlov EP, Harman SM, Merriam GR. et al. Responses of growth hormone (GH) and somatomedin-C to GH-releasing hormone in healthy aging men. J Clin Endocrinol Metab 1986; 62: 595-600
- 14 Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest 2003; 26: 799-813
- 15 Dumbell R. An appetite for growth: the role of the hypothalamic – pituitary – growth hormone axis in energy balance. J Neuroendocrinol 2022; 34: e13133
- 16 Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab 2013; 27: 541-555
- 17 Broglio F, Benso A, Castiglioni C. et al. The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab 2003; 88: 1537-1542
- 18 Ghigo E, Arvat E, Giordano R. et al. Biologic activities of growth hormone secretagogues in humans. Endocrine 2001; 14: 87-93
- 19 Forbes GB, Halloran E. The adult decline in lean body mass. Hum Biol 1976; 48: 161-173
- 20 Tzankoff SP, Norris AH. Effect of muscle mass decrease on age-related BMR changes. J Appl Physiol Respir Environ Exerc Physiol 1977; 43: 1001-1006
- 21 Schranner D, Kastenmuller G, Schonfelder M. et al. Metabolite concentration changes in humans after a bout of exercise: a systematic review of exercise metabolomics studies. Sports Med Open 2020; 6: 11
- 22 Pang Y, Kartsonaki C, Du H. et al. Physical activity, sedentary leisure time, circulating metabolic markers, and risk of major vascular diseases. Circ Genom Precis Med 2019; 12: 386-396
- 23 Fleg JL. Exercise therapy for older heart failure patients. Heart Fail Clin 2017; 13: 607-617
- 24 Huang G, Gibson CA, Tran ZV. et al. Controlled endurance exercise training and VO2max changes in older adults: a meta-analysis. Prev Cardiol 2005; 8: 217-225
- 25 Theou O, Stathokostas L, Roland KP. et al. The effectiveness of exercise interventions for the management of frailty: a systematic review. J Aging Res 2011; 2011: 569194
- 26 Birzniece V. Exercise and the growth hormone–insulin-like growth factor axis. Curr Opin Endocr Metab Res 2019; 9: 1-7
- 27 Caicedo D, Diaz O, Devesa P. et al. Growth hormone (GH) and cardiovascular system. Int J Mol Sci 2018; 19: 290
- 28 de Vries WR, Schers TJ, Ait Abdesselam S. et al. Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. Int J Sports Med 2003; 24: 208-211
- 29 Belizário JE, Garay-Malpartida M. Growth hormone, immunosenescence and vaccination failure in the elderly. Clin Immunol Commun 2023; 3: 51-57
- 30 Gelato MC. Growth hormone-insulinlike growth factor I and immune function. Trends Endocrinol Metab 1993; 4: 106-110
- 31 Du L, Ho BM, Zhou L. et al. Growth hormone releasing hormone signaling promotes Th17 cell differentiation and autoimmune inflammation. Nat Commun 2023; 14: 3298
- 32 Rudman D, Feller AG, Nagraj HS. et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6
- 33 Jorgensen JO, Pedersen SA, Thuesen L. et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; 1: 1221-1225
- 34 Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency – benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne) 2013; 4: 64
- 35 Bamba V, Kanakatti Shankar R. Approach to the patient: safety of growth hormone replacement in children and adolescents. J Clin Endocrinol Metab 2022; 107: 847-861
- 36 Slagboom TNA, van Bunderen CC, van der Lely AJ. et al. Sex differences in long-term safety and tolerability of GH replacement therapy in GH deficient adults. J Clin Endocrinol Metab 2023; 108: e415-e424
- 37 Cohn L, Feller AG, Draper MW. et al. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin Endocrinol (Oxf) 1993; 39: 417-425
- 38 Garcia JM, Merriam GR, Kargi AY. Growth hormone in aging. In: Feingold KR, Anawalt B, Blackman MR et al. (eds.). Endotext. South Dartmouth (MA): MDText.com, Inc.; Copyright 2000-2025, MDText.com, Inc. 2000
- 39 Boguszewski CL. Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk. Best Pract Res Clin Endocrinol Metab 2023; 37: 101817
- 40 Boguszewski MCS, Boguszewski CL, Chemaitilly W. et al. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol 2022; 186: P35-P52
- 41 Chae HW, Kim DH, Kim HS. Growth hormone treatment and risk of malignancy. Korean J Pediatr 2015; 58: 41-46
- 42 Kopchick JJ, Basu R, Berryman DE. et al. Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer. Nat Rev Endocrinol 2022; 18: 558-573
- 43 Friedrich N, Thuesen B, Jorgensen T. et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 2012; 35: 768-773
- 44 Kawai M, Rosen CJ. The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am 2012; 41: 323-333 vi
- 45 Puche JE, Castilla-Cortazar I. Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J Transl Med 2012; 10: 224
- 46 Mao K, Quipildor GF, Tabrizian T. et al. Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. Nat Commun 2018; 9: 2394
- 47 Coschigano KT, Clemmons D, Bellush LL. et al. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 2000; 141: 2608-2613
- 48 Junnila RK, List EO, Berryman DE. et al. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol 2013; 9: 366-376
- 49 Andrikopoulos S, Hull RL, Verchere CB. et al. Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide. Am J Physiol Endocrinol Metab 2004; 286: E418-E424
- 50 Nelson JF, Strong R, Bokov A. et al. Probing the relationship between insulin sensitivity and longevity using genetically modified mice. J Gerontol A Biol Sci Med Sci 2012; 67: 1332-1338
- 51 Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 2013; 87: 201-223
- 52 Klement RJ, Fink MK. Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis 2016; 5: e193
- 53 Perez-Gomez JM, Montero-Hidalgo AJ, Luque RM. GHRH and reproductive systems: mechanisms, functions, and clinical implications. Rev Endocr Metab Disord 2025; 26: 507-524
- 54 Vittone J, Blackman MR, Busby-Whitehead J. et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997; 46: 89-96
- 55 Ayling CM, Moreland BH, Zanelli JM. et al. Human growth hormone treatment of hypophysectomized rats increases the proportion of type-1 fibres in skeletal muscle. J Endocrinol 1989; 123: 429-435
- 56 Dilley RJ, Schwartz SM. Vascular remodeling in the growth hormone transgenic mouse. Circ Res 1989; 65: 1233-1240
- 57 Ye R, Wang HL, Zeng DW. et al. GHRH expression plasmid improves osteoporosis and skin damage in aged mice. Growth Horm IGF Res 2021; 60–61: 101429
- 58 Gesmundo I, Miragoli M, Carullo P. et al. Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure. Proc Natl Acad Sci U S A 2017; 114: 12033-12038
- 59 Kanashiro-Takeuchi R, Takeuchi L, Balkan W. et al. Growth hormone releasing hormone agonist improves cardiometabolic parameters in a murine model of heart failure with preserved ejection fraction. J Card Fail 2023; 29: 567-567
- 60 Ren HL, Cai R, Xue R. et al. Growth hormone-releasing hormone agonist attenuates vascular calcification in diabetic db/db mice. Front Cardiovasc Med 2023; 10: 1102525
- 61 Steenblock C, Bornstein SR. GHRH in diabetes and metabolism. Rev Endocr Metab Disord 2025; 26: 413-426
- 62 Osterstock G, Mitutsova V, Barre A. et al. Somatostatin triggers rhythmic electrical firing in hypothalamic GHRH neurons. Sci Rep 2016; 6: 24394
- 63 Banks WA, Morley JE, Farr SA. et al. Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. Proc Natl Acad Sci U S A 2010; 107: 22272-22277
- 64 Aleman A, Verhaar HJ, De Haan EH. et al. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab 1999; 84: 471-475
- 65 Molitch ME, Clemmons DR, Malozowski S. et al. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1587-1609
- 66 Veldhuis JD, Patrie JM, Frick K. et al. Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women. Eur J Endocrinol 2005; 153: 669-677
- 67 Arnold JR, Arnold DF, Marland A. et al. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf) 2009; 70: 435-438
- 68 Vitiello MV, Moe KE, Merriam GR. et al. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging 2006; 27: 318-323
- 69 Baker LD, Barsness SM, Borson S. et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 2012; 69: 1420-1429
- 70 Friedman SD, Baker LD, Borson S. et al. Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol 2013; 70: 883-890
- 71 Louzada RA, Blandino-Rosano M, Flores S. et al. GHRH agonist MR-409 protects beta-cells from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 2023; 120: e2209810120
- 72 Ludwig B, Rotem A, Schmid J. et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A 2012; 109: 5022-5027
- 73 Rodrigues-Dos-Santos K, Soares GM, Guimaraes D. et al. Effects of growth hormone-releasing hormone agonistic analog MR-409 on insulin-secreting cells under cyclopiazonic acid-induced endoplasmic reticulum stress. Mol Cell Endocrinol 2021; 535: 111379
- 74 Adkins-Jablonsky J, Lasher AT, Patki A. et al. Growth hormone-releasing hormone deficiency confers extended lifespan and metabolic resilience during high-fat feeding in mid and late life. Aging Cell 2024; 23: e14238
- 75 Aguiar-Oliveira MH, Oliveira FT, Pereira RM. et al. Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J Clin Endocrinol Metab 2010; 95: 714-721
- 76 Besson A, Salemi S, Gallati S. et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab 2003; 88: 3664-3667
- 77 Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M. et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3: 70ra13